Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment.

Manzella L, Massimino M, Stella S, Tirrò E, Pennisi MS, Martorana F, Motta G, Vitale SR, Puma A, Romano C, Di Gregorio S, Russo M, Malandrino P, Vigneri P.

Int J Mol Sci. 2019 Jul 2;20(13). pii: E3258. doi: 10.3390/ijms20133258. Review.

2.

Effect of low-dose tungsten on human thyroid stem/precursor cells and their progeny.

Gianì F, Pandini G, Scalisi NM, Vigneri P, Fazzari C, Malandrino P, Russo M, Masucci R, Belfiore A, Pellegriti G, Vigneri R.

Endocr Relat Cancer. 2019 May 1. pii: ERC-19-0176.R1. doi: 10.1530/ERC-19-0176. [Epub ahead of print]

PMID:
31146257
3.

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.

Stella S, Zammit V, Vitale SR, Pennisi MS, Massimino M, Tirrò E, Forte S, Spitaleri A, Antolino A, Siracusa S, Accurso V, Mannina D, Impera S, Musolino C, Russo S, Malato A, Mineo G, Musso M, Porretto F, Martino B, Di Raimondo F, Manzella L, Vigneri P, Stagno F.

Int J Mol Sci. 2019 May 6;20(9). pii: E2226. doi: 10.3390/ijms20092226.

4.

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53.

Tirrò E, Massimino M, Romano C, Pennisi MS, Stella S, Vitale SR, Fidilio A, Manzella L, Parrinello NL, Stagno F, Palumbo GA, La Cava P, Romano A, Di Raimondo F, Vigneri PG.

Front Oncol. 2019 Feb 18;9:57. doi: 10.3389/fonc.2019.00057. eCollection 2019.

5.

Insulin Receptor Isoforms in Cancer.

Vella V, Milluzzo A, Scalisi NM, Vigneri P, Sciacca L.

Int J Mol Sci. 2018 Nov 16;19(11). pii: E3615. doi: 10.3390/ijms19113615. Review.

6.

Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.

Pirosa MC, Leotta S, Cupri A, Stella S, Martino EA, Scalise L, Sapienza G, Calafiore V, Mauro E, Spadaro A, Vigneri P, Di Raimondo F, Milone G.

Chemotherapy. 2018;63(4):220-224. doi: 10.1159/000492941. Epub 2018 Oct 29.

7.

An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA.

Vitale SR, Sieuwerts AM, Beije N, Kraan J, Angus L, Mostert B, Reijm EA, Van NM, van Marion R, Dirix LY, Hamberg P, de Jongh FE, Jager A, Foekens JA, Vigneri P, Sleijfer S, Jansen MPHM, Martens JWM.

J Mol Diagn. 2019 Jan;21(1):123-137. doi: 10.1016/j.jmoldx.2018.08.010. Epub 2018 Oct 6.

PMID:
30296589
8.

DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop.

Vella V, Nicolosi ML, Cantafio P, Massimino M, Lappano R, Vigneri P, Ciuni R, Gangemi P, Morrione A, Malaguarnera R, Belfiore A.

Endocr Relat Cancer. 2019 Jan 1;26(1):197-214. doi: 10.1530/ERC-18-0310.

PMID:
30121624
9.

Ground glass opacities management in the lung cancer screening era.

Migliore M, Fornito M, Palazzolo M, Criscione A, Gangemi M, Borrata F, Vigneri P, Nardini M, Dunning J.

Ann Transl Med. 2018 Mar;6(5):90. doi: 10.21037/atm.2017.07.28. Review.

10.

Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.

Massimino M, Stella S, Tirrò E, Romano C, Pennisi MS, Puma A, Manzella L, Zanghì A, Stagno F, Di Raimondo F, Vigneri P.

Mol Cancer. 2018 Feb 19;17(1):56. doi: 10.1186/s12943-018-0805-1. Review.

11.

Anaplastic Thyroid Cancer in Sicily: The Role of Environmental Characteristics.

Tavarelli M, Malandrino P, Vigneri P, Richiusa P, Maniglia A, Violi MA, Sapuppo G, Vella V, Dardanoni G, Vigneri R, Pellegriti G.

Front Endocrinol (Lausanne). 2017 Oct 20;8:277. doi: 10.3389/fendo.2017.00277. eCollection 2017.

12.

High BCR-ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib.

Vigneri P, Stagno F, Stella S, Cupri A, Forte S, Massimino M, Antolino A, Siragusa S, Mannina D, Impera SS, Musolino C, Malato A, Mineo G, Tomaselli C, Murgano P, Musso M, Morabito F, Molica S, Martino B, Manzella L, Müller MC, Hochhaus A, Raimondo FD.

Clin Cancer Res. 2017 Dec 1;23(23):7189-7198. doi: 10.1158/1078-0432.CCR-17-0962. Epub 2017 Sep 19.

13.

Preventive Effect of Cow's Milk Fermented with Lactobacillus paracasei CBA L74 on Common Infectious Diseases in Children: A Multicenter Randomized Controlled Trial.

Corsello G, Carta M, Marinello R, Picca M, De Marco G, Micillo M, Ferrara D, Vigneri P, Cecere G, Ferri P, Roggero P, Bedogni G, Mosca F, Paparo L, Nocerino R, Berni Canani R.

Nutrients. 2017 Jun 27;9(7). pii: E669. doi: 10.3390/nu9070669.

14.

New Insights in Thyroid Cancer and p53 Family Proteins.

Manzella L, Stella S, Pennisi MS, Tirrò E, Massimino M, Romano C, Puma A, Tavarelli M, Vigneri P.

Int J Mol Sci. 2017 Jun 21;18(6). pii: E1325. doi: 10.3390/ijms18061325. Review.

15.

Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells.

Vella V, Malaguarnera R, Nicolosi ML, Palladino C, Spoleti C, Massimino M, Vigneri P, Purrello M, Ragusa M, Morrione A, Belfiore A.

Oncotarget. 2017 Jun 27;8(26):43248-43270. doi: 10.18632/oncotarget.18020.

16.

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.

Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G; GIMEMA CML Working Party.

Am J Hematol. 2017 Aug;92(8):797-805. doi: 10.1002/ajh.24774. Epub 2017 May 30.

17.

Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer.

Banna GL, Anile G, Russo G, Vigneri P, Castaing M, Nicolosi M, Strano S, Gieri S, Spina R, Patanè D, Calcara G, Fraggetta F, Marletta F, Stefano A, Ippolito M.

Oncology. 2017;92(1):39-47. doi: 10.1159/000448005. Epub 2016 Nov 11.

PMID:
27832654
18.

Heavy metals in the volcanic environment and thyroid cancer.

Vigneri R, Malandrino P, Gianì F, Russo M, Vigneri P.

Mol Cell Endocrinol. 2017 Dec 5;457:73-80. doi: 10.1016/j.mce.2016.10.027. Epub 2016 Oct 26. Review.

PMID:
27794445
19.

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.

Castagnetti F, Di Raimondo F, De Vivo A, Spitaleri A, Gugliotta G, Fabbiano F, Capodanno I, Mannina D, Salvucci M, Antolino A, Marasca R, Musso M, Crugnola M, Impera S, Trabacchi E, Musolino C, Cavazzini F, Mineo G, Tosi P, Tomaselli C, Rizzo M, Siragusa S, Fogli M, Ragionieri R, Zironi A, Soverini S, Martinelli G, Cavo M, Vigneri P, Stagno F, Rosti G, Baccarani M.

Am J Hematol. 2017 Jan;92(1):82-87. doi: 10.1002/ajh.24591. Epub 2016 Nov 18.

20.

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.

Latagliata R, Stagno F, Annunziata M, Abruzzese E, Iurlo A, Guarini A, Fava C, Gozzini A, Bonifacio M, Sorà F, Leonetti Crescenzi S, Bocchia M, Crugnola M, Castagnetti F, Capodanno I, Galimberti S, Feo C, Porrini R, Pregno P, Rizzo M, Antolino A, Mauro E, Sgherza N, Luciano L, Tiribelli M, Russo Rossi A, Trawinska M, Vigneri P, Breccia M, Rosti G, Alimena G.

Neoplasia. 2016 Sep;18(9):536-40. doi: 10.1016/j.neo.2016.07.005.

21.

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.

Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A.

Oncotarget. 2016 Nov 29;7(48):80083-80090. doi: 10.18632/oncotarget.11657.

22.

Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients.

Giallongo C, Romano A, Parrinello NL, La Cava P, Brundo MV, Bramanti V, Stagno F, Vigneri P, Chiarenza A, Palumbo GA, Tibullo D, Di Raimondo F.

PLoS One. 2016 Jul 8;11(7):e0158392. doi: 10.1371/journal.pone.0158392. eCollection 2016.

23.

Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.

Stagno F, Stella S, Spitaleri A, Pennisi MS, Di Raimondo F, Vigneri P.

Expert Rev Anticancer Ther. 2016;16(3):273-8. doi: 10.1586/14737140.2016.1151356. Review.

PMID:
26852913
24.

Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia.

Manzella L, Tirrò E, Pennisi MS, Massimino M, Stella S, Romano C, Vitale SR, Vigneri P.

Curr Cancer Drug Targets. 2016;16(7):594-605. Review.

PMID:
26728039
25.

Biomarkers and prognostic factors for malignant pleural mesothelioma.

Vigneri P, Martorana F, Manzella L, Stella S.

Future Oncol. 2015;11(24 Suppl):29-33. doi: 10.2217/fon.15.317. Review.

PMID:
26638920
26.

The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy.

Vigneri PG, Tirrò E, Pennisi MS, Massimino M, Stella S, Romano C, Manzella L.

Front Oncol. 2015 Oct 15;5:230. doi: 10.3389/fonc.2015.00230. eCollection 2015. Review.

27.

Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release.

Ishii Y, Nhiayi MK, Tse E, Cheng J, Massimino M, Durden DL, Vigneri P, Wang JY.

PLoS One. 2015 Oct 16;10(10):e0140585. doi: 10.1371/journal.pone.0140585. eCollection 2015.

28.

Several Site-specific Cancers are Increased in the Volcanic Area in Sicily.

Russo M, Malandrino P, Addario WP, Dardanoni G, Vigneri P, Pellegriti G, Squatrito S, Vigneri R.

Anticancer Res. 2015 Jul;35(7):3995-4001.

PMID:
26124347
29.

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques.

Recchia AG, Caruso N, Bossio S, Pellicanò M, De Stefano L, Franzese S, Palummo A, Abbadessa V, Lucia E, Gentile M, Vigna E, Caracciolo C, Agostino A, Galimberti S, Levato L, Stagno F, Molica S, Martino B, Vigneri P, Di Raimondo F, Morabito F.

PLoS One. 2015 Jun 25;10(6):e0130360. doi: 10.1371/journal.pone.0130360. eCollection 2015.

30.

The changing epidemiology of thyroid cancer: why is incidence increasing?

Vigneri R, Malandrino P, Vigneri P.

Curr Opin Oncol. 2015 Jan;27(1):1-7. doi: 10.1097/CCO.0000000000000148. Review.

PMID:
25310641
31.

Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.

Giallongo C, Parrinello N, Tibullo D, La Cava P, Romano A, Chiarenza A, Barbagallo I, Palumbo GA, Stagno F, Vigneri P, Di Raimondo F.

PLoS One. 2014 Jul 11;9(7):e101848. doi: 10.1371/journal.pone.0101848. eCollection 2014.

32.

Biological effects of insulin and its analogs on cancer cells with different insulin family receptor expression.

Sciacca L, Cassarino MF, Genua M, Vigneri P, Giovanna Pennisi M, Malandrino P, Squatrito S, Pezzino V, Vigneri R.

J Cell Physiol. 2014 Nov;229(11):1817-21. doi: 10.1002/jcp.24635.

PMID:
24683100
33.

IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.

Massimino M, Consoli ML, Mesuraca M, Stagno F, Tirrò E, Stella S, Pennisi MS, Romano C, Buffa P, Bond HM, Morrone G, Sciacca L, Di Raimondo F, Manzella L, Vigneri P.

Carcinogenesis. 2014 May;35(5):1132-43. doi: 10.1093/carcin/bgu013. Epub 2014 Jan 20.

PMID:
24445143
34.

Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.

Breccia M, Alimena G, Baccarani M, Bocchia M, Di Raimondo F, Gambacorti-Passerini C, Gozzini A, Morra E, Pane F, Pregno P, Rege-Cambrin G, Rosti G, Specchia G, Vigneri P, Saglio G.

Crit Rev Oncol Hematol. 2014 Jun;90(3):181-9. doi: 10.1016/j.critrevonc.2013.12.010. Epub 2013 Dec 17.

PMID:
24405858
35.

BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein.

Buffa P, Romano C, Pandini A, Massimino M, Tirrò E, Di Raimondo F, Manzella L, Fraternali F, Vigneri PG.

FASEB J. 2014 Mar;28(3):1221-36. doi: 10.1096/fj.13-236992. Epub 2013 Dec 2.

PMID:
24297701
36.

Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients.

Sciacca L, Vigneri R, Tumminia A, Frasca F, Squatrito S, Frittitta L, Vigneri P.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):808-15. doi: 10.1016/j.numecd.2013.05.006. Epub 2013 Aug 7. Review.

PMID:
23932729
37.

Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway.

Frasca F, Vella V, Nicolosi ML, Messina RL, Gianì F, Lotta S, Vigneri P, Regalbuto C, Vigneri R.

J Clin Endocrinol Metab. 2013 Jun;98(6):2502-12. doi: 10.1210/jc.2012-3623. Epub 2013 Apr 4.

PMID:
23559083
38.

Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs.

Stella S, Tirrò E, Conte E, Stagno F, Di Raimondo F, Manzella L, Vigneri P.

Mol Cancer Ther. 2013 Jun;12(6):1085-98. doi: 10.1158/1535-7163.MCT-12-0550. Epub 2013 Mar 27.

39.

Basal insulin and cardiovascular and other outcomes.

Vigneri R, Vigneri P, Frittitta L.

N Engl J Med. 2012 Nov 1;367(18):1761-2; author reply 1763-4. doi: 10.1056/NEJMc1210553. No abstract available.

PMID:
23113494
40.

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.

Tiribelli M, Latagliata R, Luciano L, Castagnetti F, Gozzini A, Cambrin GR, Annunziata M, Stagno F, Pregno P, Albano F, Abruzzese E, Musto P, Montefusco E, Fava C, Fanin R, Pane F, Rosti G, Breccia M, Alimena G, Vigneri P.

Ann Hematol. 2013 Jan;92(2):179-83. doi: 10.1007/s00277-012-1591-2. Epub 2012 Oct 10.

PMID:
23053188
41.

Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocythaemia and myelofibrosis patients.

Vicari L, Martinetti D, Buccheri S, Colarossi C, Aiello E, Stagno F, Villari L, Cavalli M, Di Raimondo F, Gulisano M, De Maria R, Vigneri P.

Br J Haematol. 2012 Oct;159(2):237-40. doi: 10.1111/j.1365-2141.2012.09246.x. Epub 2012 Aug 24. No abstract available.

PMID:
22924455
42.

Infliximab therapy in hematologic malignancies: handle with care.

Stagno F, Vigneri P, Cupri A, Vitale SR, Di Raimondo F.

Haematologica. 2012 Aug;97(8):e26; author reply e27. doi: 10.3324/haematol.2012.067934. No abstract available.

43.

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.

Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G.

Hematol Oncol. 2013 Jun;31(2):103-9. doi: 10.1002/hon.2020. Epub 2012 Jul 19. Erratum in: Hematol Oncol. 2013 Spe;31(3):169.

PMID:
22815278
44.

Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment.

Stagno F, Vigneri P, Cupri A, Stella S, Di Raimondo F.

Leuk Res. 2012 Sep;36(9):1208-9. doi: 10.1016/j.leukres.2012.05.024. Epub 2012 Jun 20. No abstract available.

PMID:
22726921
45.

Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy.

Stagno F, Vigneri P, Di Raimondo F.

Int J Hematol. 2012 Jul;96(1):142-3. doi: 10.1007/s12185-012-1113-y. Epub 2012 May 26. No abstract available.

PMID:
22639055
46.

IRF5 promotes the proliferation of human thyroid cancer cells.

Massimino M, Vigneri P, Fallica M, Fidilio A, Aloisi A, Frasca F, Manzella L.

Mol Cancer. 2012 Apr 16;11:21. doi: 10.1186/1476-4598-11-21.

47.

Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia.

Stagno F, Vigneri P, Di Raimondo F.

Leuk Res. 2012 Jul;36(7):803. doi: 10.1016/j.leukres.2012.03.016. Epub 2012 Apr 12. No abstract available.

PMID:
22502918
48.

Diagnosis of blastic phase of chronic myeloid leukemia.

Stagno F, Vigneri P, Cupri A, Vitale SR, Di Raimondo F.

Acta Haematol. 2012;127(4):198. doi: 10.1159/000337267. Epub 2012 Mar 21. No abstract available.

PMID:
22441204
49.

Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia.

Stagno F, Vigneri P, Consoli ML, Cupri A, Stella S, Tambè L, Massimino M, Manzella L, Di Raimondo F.

Acta Haematol. 2012;127(1):7-9. doi: 10.1159/000330607. Epub 2011 Oct 5. No abstract available.

PMID:
21986290
50.

BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint.

Giallongo C, Tibullo D, La Cava P, Branca A, Parrinello N, Spina P, Stagno F, Conticello C, Chiarenza A, Vigneri P, Palumbo GA, Di Raimondo F.

Acta Haematol. 2011;126(4):205-10. doi: 10.1159/000329911. Epub 2011 Sep 16. Erratum in: Acta Haematol. 2011;126(4):210. Acta Haematol. 2012;127(2):80.

PMID:
21934293

Supplemental Content

Loading ...
Support Center